Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Receives Average Recommendation of “Buy” from Brokerages

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) has earned an average rating of “Buy” from the five research firms that are covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have covered the stock in the last year is $25.72.

ATNM has been the subject of a number of research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $21.00 price target on shares of Actinium Pharmaceuticals in a research note on Monday, April 1st. Maxim Group increased their price target on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, March 19th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Actinium Pharmaceuticals in a research note on Monday, April 1st. Finally, StockNews.com lowered Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, March 19th.

Institutional Trading of Actinium Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Sanders Morris Harris LLC purchased a new stake in shares of Actinium Pharmaceuticals during the first quarter worth $78,000. Creative Financial Designs Inc. ADV raised its holdings in shares of Actinium Pharmaceuticals by 19.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 3,175 shares in the last quarter. Finally, Brandywine Global Investment Management LLC purchased a new stake in shares of Actinium Pharmaceuticals during the third quarter worth $1,033,000. Hedge funds and other institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Stock Performance

ATNM opened at $6.56 on Friday. Actinium Pharmaceuticals has a 12 month low of $4.00 and a 12 month high of $9.86. The company has a market capitalization of $192.86 million, a P/E ratio of -3.58 and a beta of 0.01.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last posted its earnings results on Friday, March 29th. The biotechnology company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.21. The business had revenue of $0.08 million during the quarter. As a group, research analysts expect that Actinium Pharmaceuticals will post -1.87 earnings per share for the current fiscal year.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.